NCT05057806: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- State
- Under way
- Phase
- Early Phase 1
- People
- 30 planned
- Started
- 13 Jan 2021
- Primary completion
- 30 Nov 2026
- Arms
- Empagliflozin Group
- Results
- None posted
- 13 Jan 2021: Trial started
- 27 Sep 2021: Trial registered